Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

Market Cap	22.61B -16.6%
Revenue (ttm)	4.41B -20.2%
Net Income	591.52M -55.7%
EPS	0.26 -56.4%
Shares Out	2.23B
PE Ratio	38.76
Forward PE	24.73
Dividend	0.17 (1.71%)
Ex-Dividend Date	Apr 29, 2026

Volume	10,461,890
Average Volume	12,633,049
Open	9.97
Previous Close	9.98
Day's Range	9.96 - 10.14
52-Week Range	9.60 - 14.74
Beta	0.12
RSI	46.16
Earnings Date	Aug 18, 2026

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. It offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxychol...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,126
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301301

Financial Performance

In 2025, SHE:301301's revenue was 4.62 billion, a decrease of -19.83% compared to the previous year's 5.76 billion. Earnings were 769.01 million, a decrease of -45.08%.